Global Protein Drugs Market- Industry Analysis, Growth, Segmentation and Forecast-2019-2027

The global protein drugs market was valued $xx Mn. in 2019 and is expected to reach $xx Mn in 2027, at a CAGR of xx%.

Global Protein Drugs Market Introduction and Overview

Protein drugs are artificially synthesized proteins for treatment of chronic diseases such as cancer and diabetes. They are fast-acting medicines capable of delivering small protein molecules to the body in specific amount. Protein drugs has become an important segment of the healthcare industry and has a high demand. Advances in biological sciences have shown a positive impact on the global protein drugs market. The future of this market is expected to be promising due to rise in prevalence of chronic diseases, unmet needs for effective treatments and advances in drug development and manufacturing. Advantages of protein drugs such as their efficiency, efficacy and low toxicity are boosting the market growth. Factors such as rising R&D activities, increasing pharmaceutical industries, rapid advances in genetic engineering are the key drivers to the market. Increasing adoption of protein drugs in emerging economies is expected to grow opportunities for the market in future. However, high costs of drugs due to expensive procedures and complex approval processes are restraining the market growth. The report covers the detailed analysis of global market for protein drugs with the classifications of the market based on products, applications and region. Analysis of past market dynamics from 2016 to 2019 is given in the report, which will help readers to benchmark the past trends with current market scenarios with the key players contribution in it. The report has profiled seventeen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analysing the market and estimation the size of the same. The growing healthcare infrastructure in each region is different and focus is given on availability of advanced technology and new techniques. Report has come up with recommendations for future hot spot in APAC region. New research findings, funding policies for projects and its impact on global protein drugs market are covered in the report.

Global Protein Drugs Market Segment Analysis

The monoclonal antibodies segment is expected to grow at a CAGR of 14.4% in the forecast period owing to the rising prevalence of cancer cases. Increasing research collaborations for development of strong drug pipelines is a major factor driving the market growth. The success of mAbs such as Avastin, Herceptin and Rituxan earned a revenue of $xx, $xx and $xx Mn in 2019. The success of these antibodies increased the interest of manufacturers to invest in the segment. In March 2019, FDA approved Trazimera for the treatment of metastatic gastric adenocarcinoma and HER2 breast cancer, thereby fuelling the market growth. In July 2020, UCB announced a licensed agreement with Roche and Genentech for the development of UCB0107, a monoclonal antibody potential for treating patients with Supranuclear palsy (PSP) and Alzheimer’s. An increasing number of government initiatives and funding for clinical trials of drugs, which can be used in the treatment of COVID-19 are expected to favour the segment growth. Global Protein Drugs Market To know about the Research Methodology :- Request Free Sample Report

Global Protein Drugs Market Segmentation

The Global protein Drugs Market is segmented based on-

Products

• Monoclonal Antibodies • Insulin • Fusion Protein • Erythropoietin • Interferon

Applications

• Metabolic Disorders • Immunologic Disorders • Haematological Disorders • Cancer • Genetic Disorders • Hormonal Disorders

Scope of the report: Inquire before buying

Global Protein Drugs Market Regional Insights

Global Protein Drugs Market1 North America generated a revenue of $xx Mn in 2019 and is expected to emerge as a dominant region in the forecast period. Increasing prevalence cancer cases, growing research activities, advanced treatment techniques, favourable reimbursement policies, development of novel products are the multiple factors boosting the growth of market in this region Asia Pacific is expected to witness growth in the forecast period. Owing to the increasing population and rising diabetic cases, growing healthcare facilities in developing nations and advanced treatment options, the market in this region is anticipated to grow.

Key players operating the Global Protein Drugs Market

• Abbott Laboratories • AstraZeneca • Amgen Inc • Baxter International Inc • Eli Lilly and Company • F.Hoffmann-La Roche Ltd • Johnson & Johnson • Merck & Co, Inc • Novo Nordisk A/S • Pfizer Inc • Sanofi • UCB Group • Genentech Inc • Teva Pharmaceuticals • Biogen Inc • Novartis • Generex Biotechnology
Global Protein Drugs Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: PROTEIN DRUGS Market Size, By Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global PROTEIN DRUGS Market Analysis and Forecast 6.1. PROTEIN DRUGS Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global PROTEIN DRUGS Market Analysis and Forecast, By Products 7.1. Introduction and Definition 7.2. Key Findings 7.3. PROTEIN DRUGS Market Value Share Analysis, By Products 7.4. PROTEIN DRUGS Market Size (US$ Mn) Forecast, By Products 7.5. PROTEIN DRUGS Market Analysis, By Products 7.6. PROTEIN DRUGS Market Attractiveness Analysis, By Products 8. Global PROTEIN DRUGS Market Analysis and Forecast, By Applications 8.1. Introduction and Definition 8.2. Key Findings 8.3. PROTEIN DRUGS Market Value Share Analysis, By Applications 8.4. PROTEIN DRUGS Market Size (US$ Mn) Forecast, By Applications 8.5. PROTEIN DRUGS Market Analysis, By Applications 8.6. PROTEIN DRUGS Market Attractiveness Analysis, By Applications 9. Global PROTEIN DRUGS Market Analysis, By Region 9.1. PROTEIN DRUGS Market Value Share Analysis, By Region 9.2. PROTEIN DRUGS Market Size (US$ Mn) Forecast, By Region 9.3. PROTEIN DRUGS Market Attractiveness Analysis, By Region 10. North America PROTEIN DRUGS Market Analysis 10.1. Key Findings 10.2. North America PROTEIN DRUGS Market Overview 10.3. North America PROTEIN DRUGS Market Value Share Analysis, By Products 10.4. North America PROTEIN DRUGS Market Forecast, By Products 10.4.1. Monoclonal Antibodies 10.4.2. Insulin 10.4.3. Fusion Protein 10.4.4. Erythropoietin 10.4.5. Interferon 10.5. North America PROTEIN DRUGS Market Value Share Analysis, By Applications 10.6. North America PROTEIN DRUGS Market Forecast, By Applications 10.6.1. Metabolic Disorders 10.6.2. Immunologic Disorders 10.6.3. Haematological Disorders 10.6.4. Cancer 10.6.5. Genetic Disorders 10.6.6. Hormonal Disorders 10.7. North America PROTEIN DRUGS Market Value Share Analysis, By Country 10.8. North America PROTEIN DRUGS Market Forecast, By Country 10.8.1. U.S. 10.8.2. Canada 10.8.3. Mexico 10.9. North America PROTEIN DRUGS Market Analysis, By Country 10.10. U.S. PROTEIN DRUGS Market Forecast, By Products 10.10.1. Monoclonal Antibodies 10.10.2. Insulin 10.10.3. Fusion Protein 10.10.4. Erythropoietin 10.10.5. Interferon 10.11. U.S. PROTEIN DRUGS Market Forecast, By Applications 10.11.1. Metabolic Disorders 10.11.2. Immunologic Disorders 10.11.3. Haematological Disorders 10.11.4. Cancer 10.11.5. Genetic Disorders 10.11.6. Hormonal Disorders 10.12. Canada PROTEIN DRUGS Market Forecast, By Products 10.12.1. Monoclonal Antibodies 10.12.2. Insulin 10.12.3. Fusion Protein 10.12.4. Erythropoietin 10.12.5. Interferon 10.13. Canada PROTEIN DRUGS Market Forecast, By Applications 10.13.1. Metabolic Disorders 10.13.2. Immunologic Disorders 10.13.3. Haematological Disorders 10.13.4. Cancer 10.13.5. Genetic Disorders 10.13.6. Hormonal Disorders 10.14. Mexico PROTEIN DRUGS Market Forecast, By Products 10.14.1. Monoclonal Antibodies 10.14.2. Insulin 10.14.3. Fusion Protein 10.14.4. Erythropoietin 10.14.5. Interferon 10.15. Mexico PROTEIN DRUGS Market Forecast, By Applications 10.15.1. Metabolic Disorders 10.15.2. Immunologic Disorders 10.15.3. Haematological Disorders 10.15.4. Cancer 10.15.5. Genetic Disorders 10.15.6. Hormonal Disorders 10.16. North America PROTEIN DRUGS Market Attractiveness Analysis 10.16.1. By Products 10.16.2. By Applications 10.17. PEST Analysis 10.18. Key Trends 10.19. Key Developments 11. Europe PROTEIN DRUGS Market Analysis 11.1. Key Findings 11.2. Europe PROTEIN DRUGS Market Overview 11.3. Europe PROTEIN DRUGS Market Value Share Analysis, By Products 11.4. Europe PROTEIN DRUGS Market Forecast, By Products 11.4.1. Monoclonal Antibodies 11.4.2. Insulin 11.4.3. Fusion Protein 11.4.4. Erythropoietin 11.4.5. Interferon 11.5. Europe PROTEIN DRUGS Market Value Share Analysis, By Applications 11.6. Europe PROTEIN DRUGS Market Forecast, By Applications 11.6.1. Metabolic Disorders 11.6.2. Immunologic Disorders 11.6.3. Haematological Disorders 11.6.4. Cancer 11.6.5. Genetic Disorders 11.6.6. Hormonal Disorders 11.7. Europe PROTEIN DRUGS Market Value Share Analysis, By Country 11.8. Europe PROTEIN DRUGS Market Forecast, By Country 11.8.1. Germany 11.8.2. U.K. 11.8.3. France 11.8.4. Italy 11.8.5. Spain 11.8.6. Sweden 11.8.7. CIS countries 11.8.8. Rest of Europe 11.9. Germany PROTEIN DRUGS Market Forecast, By Products 11.9.1. Monoclonal Antibodies 11.9.2. Insulin 11.9.3. Fusion Protein 11.9.4. Erythropoietin 11.9.5. Interferon 11.10. Germany PROTEIN DRUGS Market Forecast, By Applications 11.10.1. Metabolic Disorders 11.10.2. Immunologic Disorders 11.10.3. Haematological Disorders 11.10.4. Cancer 11.10.5. Genetic Disorders 11.10.6. Hormonal Disorders 11.11. U.K. PROTEIN DRUGS Market Forecast, By Products 11.11.1. Monoclonal Antibodies 11.11.2. Insulin 11.11.3. Fusion Protein 11.11.4. Erythropoietin 11.11.5. Interferon 11.12. U.K. PROTEIN DRUGS Market Forecast, By Applications 11.12.1. Metabolic Disorders 11.12.2. Immunologic Disorders 11.12.3. Haematological Disorders 11.12.4. Cancer 11.12.5. Genetic Disorders 11.12.6. Hormonal Disorders 11.13. France PROTEIN DRUGS Market Forecast, By Products 11.13.1. Monoclonal Antibodies 11.13.2. Insulin 11.13.3. Fusion Protein 11.13.4. Erythropoietin 11.13.5. Interferon 11.14. France PROTEIN DRUGS Market Forecast, By Applications 11.14.1. Metabolic Disorders 11.14.2. Immunologic Disorders 11.14.3. Haematological Disorders 11.14.4. Cancer 11.14.5. Genetic Disorders 11.14.6. Hormonal Disorders 11.15. Italy PROTEIN DRUGS Market Forecast, By Products 11.15.1. Monoclonal Antibodies 11.15.2. Insulin 11.15.3. Fusion Protein 11.15.4. Erythropoietin 11.15.5. Interferon 11.16. Italy PROTEIN DRUGS Market Forecast, By Applications 11.16.1. Metabolic Disorders 11.16.2. Immunologic Disorders 11.16.3. Haematological Disorders 11.16.4. Cancer 11.16.5. Genetic Disorders 11.16.6. Hormonal Disorders 11.17. Spain PROTEIN DRUGS Market Forecast, By Products 11.17.1. Monoclonal Antibodies 11.17.2. Insulin 11.17.3. Fusion Protein 11.17.4. Erythropoietin 11.17.5. Interferon 11.18. Spain PROTEIN DRUGS Market Forecast, By Applications 11.18.1. Metabolic Disorders 11.18.2. Immunologic Disorders 11.18.3. Haematological Disorders 11.18.4. Cancer 11.18.5. Genetic Disorders 11.18.6. Hormonal Disorders 11.19. Sweden PROTEIN DRUGS Market Forecast, By Products 11.19.1. Monoclonal Antibodies 11.19.2. Insulin 11.19.3. Fusion Protein 11.19.4. Erythropoietin 11.19.5. Interferon 11.20. Sweden PROTEIN DRUGS Market Forecast, By Applications 11.20.1. Metabolic Disorders 11.20.2. Immunologic Disorders 11.20.3. Haematological Disorders 11.20.4. Cancer 11.20.5. Genetic Disorders 11.20.6. Hormonal Disorders 11.21. CIS countries PROTEIN DRUGS Market Forecast, By Products 11.21.1. Monoclonal Antibodies 11.21.2. Insulin 11.21.3. Fusion Protein 11.21.4. Erythropoietin 11.21.5. Interferon 11.22. CIS countries PROTEIN DRUGS Market Forecast, By Applications 11.22.1. Metabolic Disorders 11.22.2. Immunologic Disorders 11.22.3. Haematological Disorders 11.22.4. Cancer 11.22.5. Genetic Disorders 11.22.6. Hormonal Disorders 11.23. Rest of Europe PROTEIN DRUGS Market Forecast, By Products 11.23.1. Monoclonal Antibodies 11.23.2. Insulin 11.23.3. Fusion Protein 11.23.4. Erythropoietin 11.23.5. Interferon 11.24. Rest of Europe PROTEIN DRUGS Market Forecast, By Applications 11.24.1. Metabolic Disorders 11.24.2. Immunologic Disorders 11.24.3. Haematological Disorders 11.24.4. Cancer 11.24.5. Genetic Disorders 11.24.6. Hormonal Disorders 11.25. Europe PROTEIN DRUGS Market Attractiveness Analysis 11.25.1. By Applications 11.25.2. By Products 11.26. PEST Analysis 11.27. Key Trends 11.28. Key Developments 12. Asia Pacific PROTEIN DRUGS Market Analysis 12.1. Key Findings 12.2. Asia Pacific PROTEIN DRUGS Market Overview 12.3. Asia Pacific PROTEIN DRUGS Market Value Share Analysis, By Products 12.4. Asia Pacific PROTEIN DRUGS Market Forecast, By Products 12.4.1. Monoclonal Antibodies 12.4.2. Insulin 12.4.3. Fusion Protein 12.4.4. Erythropoietin 12.4.5. Interferon 12.5. Asia Pacific PROTEIN DRUGS Market Value Share Analysis, By Applications 12.6. Asia Pacific PROTEIN DRUGS Market Forecast, By Applications 12.6.1. Metabolic Disorders 12.6.2. Immunologic Disorders 12.6.3. Haematological Disorders 12.6.4. Cancer 12.6.5. Genetic Disorders 12.6.6. Hormonal Disorders 12.7. Asia Pacific PROTEIN DRUGS Market Value Share Analysis, By Country 12.8. Asia Pacific PROTEIN DRUGS Market Forecast, By Country 12.8.1. China 12.8.2. India 12.8.3. Japan 12.8.4. South Korea 12.8.5. Australia 12.8.6. ASEAN 12.8.7. Rest of Asia Pacific 12.9. Asia Pacific PROTEIN DRUGS Market Analysis, By Country 12.10. China PROTEIN DRUGS Market Forecast, By Products 12.10.1. Monoclonal Antibodies 12.10.2. Insulin 12.10.3. Fusion Protein 12.10.4. Erythropoietin 12.10.5. Interferon 12.11. China PROTEIN DRUGS Market Forecast, By Applications 12.11.1. Metabolic Disorders 12.11.2. Immunologic Disorders 12.11.3. Haematological Disorders 12.11.4. Cancer 12.11.5. Genetic Disorders 12.11.6. Hormonal Disorders 12.12. India PROTEIN DRUGS Market Forecast, By Products 12.12.1. Monoclonal Antibodies 12.12.2. Insulin 12.12.3. Fusion Protein 12.12.4. Erythropoietin 12.12.5. Interferon 12.13. India PROTEIN DRUGS Market Forecast, By Applications 12.13.1. Metabolic Disorders 12.13.2. Immunologic Disorders 12.13.3. Haematological Disorders 12.13.4. Cancer 12.13.5. Genetic Disorders 12.13.6. Hormonal Disorders 12.14. Japan PROTEIN DRUGS Market Forecast, By Products 12.14.1. Monoclonal Antibodies 12.14.2. Insulin 12.14.3. Fusion Protein 12.14.4. Erythropoietin 12.14.5. Interferon 12.15. Japan PROTEIN DRUGS Market Forecast, By Applications 12.15.1. Metabolic Disorders 12.15.2. Immunologic Disorders 12.15.3. Haematological Disorders 12.15.4. Cancer 12.15.5. Genetic Disorders 12.15.6. Hormonal Disorders 12.16. South Korea PROTEIN DRUGS Market Forecast, By Products 12.16.1. Monoclonal Antibodies 12.16.2. Insulin 12.16.3. Fusion Protein 12.16.4. Erythropoietin 12.16.5. Interferon 12.17. South Korea PROTEIN DRUGS Market Forecast, By Applications 12.17.1. Metabolic Disorders 12.17.2. Immunologic Disorders 12.17.3. Haematological Disorders 12.17.4. Cancer 12.17.5. Genetic Disorders 12.17.6. Hormonal Disorders 12.18. Australia PROTEIN DRUGS Market Forecast, By Products 12.18.1. Monoclonal Antibodies 12.18.2. Insulin 12.18.3. Fusion Protein 12.18.4. Erythropoietin 12.18.5. Interferon 12.19. Australia PROTEIN DRUGS Market Forecast, By Applications 12.19.1. Metabolic Disorders 12.19.2. Immunologic Disorders 12.19.3. Haematological Disorders 12.19.4. Cancer 12.19.5. Genetic Disorders 12.19.6. Hormonal Disorders 12.20. ASEAN PROTEIN DRUGS Market Forecast, By Products 12.20.1. Monoclonal Antibodies 12.20.2. Insulin 12.20.3. Fusion Protein 12.20.4. Erythropoietin 12.20.5. Interferon 12.21. ASEAN PROTEIN DRUGS Market Forecast, By Applications 12.21.1. Metabolic Disorders 12.21.2. Immunologic Disorders 12.21.3. Haematological Disorders 12.21.4. Cancer 12.21.5. Genetic Disorders 12.21.6. Hormonal Disorders 12.22. Rest of Asia Pacific PROTEIN DRUGS Market Forecast, By Products 12.22.1. Monoclonal Antibodies 12.22.2. Insulin 12.22.3. Fusion Protein 12.22.4. Erythropoietin 12.22.5. Interferon 12.23. Rest of Asia Pacific PROTEIN DRUGS Market Forecast, By Applications 12.23.1. Metabolic Disorders 12.23.2. Immunologic Disorders 12.23.3. Haematological Disorders 12.23.4. Cancer 12.23.5. Genetic Disorders 12.23.6. Hormonal Disorders 12.24. Asia Pacific PROTEIN DRUGS Market Attractiveness Analysis 12.24.1. By Products 12.24.2. By Applications 12.25. PEST Analysis 12.26. Key Trends 12.27. Key Developments 13. Middle East & Africa PROTEIN DRUGS Market Analysis 13.1. Key Findings 13.2. Middle East & Africa PROTEIN DRUGS Market Overview 13.3. Middle East & Africa PROTEIN DRUGS Market Value Share Analysis, By Products 13.4. Middle East & Africa PROTEIN DRUGS Market Forecast, By Products 13.4.1. Monoclonal Antibodies 13.4.2. Insulin 13.4.3. Fusion Protein 13.4.4. Erythropoietin 13.4.5. Interferon 13.5. Middle East & Africa PROTEIN DRUGS Market Value Share Analysis, By Applications 13.6. Middle East & Africa PROTEIN DRUGS Market Forecast, By Applications 13.6.1. Metabolic Disorders 13.6.2. Immunologic Disorders 13.6.3. Haematological Disorders 13.6.4. Cancer 13.6.5. Genetic Disorders 13.6.6. Hormonal Disorders 13.7. Middle East & Africa PROTEIN DRUGS Market Value Share Analysis, By Country 13.8. Middle East & Africa PROTEIN DRUGS Market Forecast, By Country 13.8.1. GCC Countries 13.8.2. South Africa 13.8.3. Nigeria 13.8.4. Egypt 13.8.5. Rest of Middle East & Africa 13.9. Middle East & Africa PROTEIN DRUGS Market Analysis, By Country 13.10. GCC Countries PROTEIN DRUGS Market Forecast, By Products 13.10.1. Monoclonal Antibodies 13.10.2. Insulin 13.10.3. Fusion Protein 13.10.4. Erythropoietin 13.10.5. Interferon 13.11. GCC Countries PROTEIN DRUGS Market Forecast, By Applications 13.11.1. Metabolic Disorders 13.11.2. Immunologic Disorders 13.11.3. Haematological Disorders 13.11.4. Cancer 13.11.5. Genetic Disorders 13.11.6. Hormonal Disorders 13.12. South Africa PROTEIN DRUGS Market Forecast, By Products 13.12.1. Monoclonal Antibodies 13.12.2. Insulin 13.12.3. Fusion Protein 13.12.4. Erythropoietin 13.12.5. Interferon 13.13. South Africa PROTEIN DRUGS Market Forecast, By Applications 13.13.1. Metabolic Disorders 13.13.2. Immunologic Disorders 13.13.3. Haematological Disorders 13.13.4. Cancer 13.13.5. Genetic Disorders 13.13.6. Hormonal Disorders 13.14. Nigeria PROTEIN DRUGS Market Forecast, By Products 13.14.1. Monoclonal Antibodies 13.14.2. Insulin 13.14.3. Fusion Protein 13.14.4. Erythropoietin 13.14.5. Interferon 13.15. Nigeria PROTEIN DRUGS Market Forecast, By Applications 13.15.1. Metabolic Disorders 13.15.2. Immunologic Disorders 13.15.3. Haematological Disorders 13.15.4. Cancer 13.15.5. Genetic Disorders 13.15.6. Hormonal Disorders 13.16. Egypt PROTEIN DRUGS Market Forecast, By Products 13.16.1. Monoclonal Antibodies 13.16.2. Insulin 13.16.3. Fusion Protein 13.16.4. Erythropoietin 13.16.5. Interferon 13.17. Egypt PROTEIN DRUGS Market Forecast, By Applications 13.17.1. Metabolic Disorders 13.17.2. Immunologic Disorders 13.17.3. Haematological Disorders 13.17.4. Cancer 13.17.5. Genetic Disorders 13.17.6. Hormonal Disorders 13.18. Rest of Middle East & Africa PROTEIN DRUGS Market Forecast, By Products 13.18.1. Monoclonal Antibodies 13.18.2. Insulin 13.18.3. Fusion Protein 13.18.4. Erythropoietin 13.18.5. Interferon 13.19. Rest of Middle East & Africa PROTEIN DRUGS Market Forecast, By Applications 13.19.1. Metabolic Disorders 13.19.2. Immunologic Disorders 13.19.3. Haematological Disorders 13.19.4. Cancer 13.19.5. Genetic Disorders 13.19.6. Hormonal Disorders 13.20. Middle East & Africa PROTEIN DRUGS Market Attractiveness Analysis 13.20.1. By Products 13.20.2. By Applications 13.21. PEST Analysis 13.22. Key Trends 13.23. Key Developments 14. South America PROTEIN DRUGS Market Analysis 14.1. Key Findings 14.2. South America PROTEIN DRUGS Market Overview 14.3. South America PROTEIN DRUGS Market Value Share Analysis, By Products 14.4. South America PROTEIN DRUGS Market Forecast, By Products 14.4.1. Monoclonal Antibodies 14.4.2. Insulin 14.4.3. Fusion Protein 14.4.4. Erythropoietin 14.4.5. Interferon 14.5. South America PROTEIN DRUGS Market Value Share Analysis, By Applications 14.6. South America PROTEIN DRUGS Market Forecast, By Applications 14.6.1. Metabolic Disorders 14.6.2. Immunologic Disorders 14.6.3. Haematological Disorders 14.6.4. Cancer 14.6.5. Genetic Disorders 14.6.6. Hormonal Disorders 14.7. South America PROTEIN DRUGS Market Value Share Analysis, By Country 14.8. South America PROTEIN DRUGS Market Forecast, By Country 14.8.1. Brazil 14.8.2. Colombia 14.8.3. Argentina 14.8.4. Rest of South America 14.9. South America PROTEIN DRUGS Market Analysis, By Country 14.10. Brazil PROTEIN DRUGS Market Forecast, By Products 14.10.1. Monoclonal Antibodies 14.10.2. Insulin 14.10.3. Fusion Protein 14.10.4. Erythropoietin 14.10.5. Interferon 14.11. Brazil PROTEIN DRUGS Market Forecast, By Applications 14.11.1. Metabolic Disorders 14.11.2. Immunologic Disorders 14.11.3. Haematological Disorders 14.11.4. Cancer 14.11.5. Genetic Disorders 14.11.6. Hormonal Disorders 14.12. Colombia PROTEIN DRUGS Market Forecast, By Products 14.12.1. Monoclonal Antibodies 14.12.2. Insulin 14.12.3. Fusion Protein 14.12.4. Erythropoietin 14.12.5. Interferon 14.13. Colombia PROTEIN DRUGS Market Forecast, By Applications 14.13.1. Metabolic Disorders 14.13.2. Immunologic Disorders 14.13.3. Haematological Disorders 14.13.4. Cancer 14.13.5. Genetic Disorders 14.13.6. Hormonal Disorders 14.14. Argentina PROTEIN DRUGS Market Forecast, By Products 14.14.1. Monoclonal Antibodies 14.14.2. Insulin 14.14.3. Fusion Protein 14.14.4. Erythropoietin 14.14.5. Interferon 14.15. Argentina PROTEIN DRUGS Market Forecast, By Applications 14.15.1. Metabolic Disorders 14.15.2. Immunologic Disorders 14.15.3. Haematological Disorders 14.15.4. Cancer 14.15.5. Genetic Disorders 14.15.6. Hormonal Disorders 14.16. Rest of South America PROTEIN DRUGS Market Forecast, By Products 14.16.1. Monoclonal Antibodies 14.16.2. Insulin 14.16.3. Fusion Protein 14.16.4. Erythropoietin 14.16.5. Interferon 14.17. Rest of South America PROTEIN DRUGS Market Forecast, By Applications 14.17.1. Metabolic Disorders 14.17.2. Immunologic Disorders 14.17.3. Haematological Disorders 14.17.4. Cancer 14.17.5. Genetic Disorders 14.17.6. Hormonal Disorders 14.18. South America PROTEIN DRUGS Market Attractiveness Analysis 14.18.1. By Products 14.18.2. By Applications 14.19. PEST Analysis 14.20. Key Trends 14.21. Key Developments 15. Company Profiles 15.1. Market Share Analysis, By Company 15.2. Competition Matrix 15.2.1. Competitive Benchmarking of key players By price, presence, market share, Applications, and R&D investment 15.2.2. New Product Launches and Product Enhancements 15.2.3. Market Consolidation 15.2.3.1. M&A By Regions, Investment and Applications 15.2.3.2. M&A Key Players, Forward Integration and Backward Integration 15.3. Company Profiles: Key Players 15.3.1. Abbott Laboratories 15.3.1.1. Company Overview 15.3.1.2. Financial Overview 15.3.1.3. Product Portfolio 15.3.1.4. Business Strategy 15.3.1.5. Recent Developments 15.3.1.6. Development Footprint 15.3.2. AstraZeneca 15.3.3. Amgen Inc 15.3.4. Baxter International Inc 15.3.5. Eli Lilly and Company 15.3.6. F.Hoffmann-La Roche Ltd 15.3.7. Johnson & Johnson 15.3.8. Merck & Co, Inc 15.3.9. Novo Nordisk A/S 15.3.10. Pfizer Inc 15.3.11. Sanofi 15.3.12. UCB Group 15.3.13. Genentech Inc 15.3.14. Teva Pharmaceuticals 15.3.15. Biogen Inc 15.3.16. Novartis 15.3.17. Generex Biotechnology

About This Report

Report ID 82226
Category Healthcare
Published Date February 2021
Updated Date
Contact Us